# Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

> **NCT05473741** · — · COMPLETED · sponsor: **Centre for Addiction and Mental Health** · enrollment: 51 (actual)

## Conditions studied

- Schizophrenia
- Schizophrenia Relapse

## Interventions

- **DRUG:** Second Generation Long-Acting Injectable Antipsychotic Medications

## Key facts

- **NCT ID:** NCT05473741
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-11
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473741, "Risk of Breakthrough Symptoms With Long-Acting Injectable Medications". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05473741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*